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Abstract
Background: Food allergy can cause life threatening reactions. Currently, patients with severe food allergy are
advised to avoid foods which provoke allergic reactions. This has become increasingly difficult as food proteins are
being added to a broader range of consumer products.
Patients and methods: Here we describe our investigations into the allergenicity of a new drink when two cow’s
milk allergic children suffered anaphylaxis after consuming Wh2ole®.
Results: Our studies have shown that in comparison with cow’s milk, Wh2ole® contains at least three times the
concentration of b-lactoglobulin. b-lactoglobulin is one of the dominant allergens in bovine milk.
Conclusions: These studies have shown that modern technology allows the creation of “hyperallergenic” foods.
These products have the potential to cause severe reactions in milk allergic persons. Avoiding inadvertent exposure
is the shared responsibility of allergic consumers, regulatory authorities and the food industry.
Introduction
Food allergy affects approximately 6% of children and
3-4% of adults [1]. Clinical manifestations can vary from
mild abdominal discomfort to death from anaphylaxis.
Currently there is no widely available specific treatment
for food allergy [2]. Patients with severe food allergy are
advised to avoid consuming foods to which they are
allergic, in order to reduce the risk of anaphylaxis.
Avoidance of foods has however become increasingly
difficult for allergic consumers. Contamination of foods
with allergenic proteins can occur from harvest/produc-
tion to the dinner table [3]. A further challenge for food
allergic persons has been the rapid advances in food
technology [4]. Proteins from a specific food can now be
isolated with ease and added to another product to
enhance its properties.
Wh2ole® is a new drink manufactured by Fonterra of
New Zealand (figure 1). Wh2ole® contains high concen-
trations (1 g/100 ml) of bovine whey proteins, which
have been added to flavoured water. The solution is a
clear transparent liquid in spite of the high concentra-
tion of milk proteins. The drink is marketed as a “bridge
for the hunger gap” between meals. It is placed on
drinks stands in supermarkets and cafes.
Here we report the results of our investigations after two
children with cow’s milk allergy suffered anaphylaxis fol-
lowing the inadvertent consumption of Wh2ole®. Wh2ole®
contains a higher concentration of b-lactoglobulin than
cow’s milk and has the potential to provoke severe reac-
tions in milk allergic persons.
Case descriptions
Patient 1
Patient 1 is an 18 month child. She developed urticaria
after her mother consumed cow’s milk and breast fed.
After weaning, she had two systemic allergic reactions
to cow’s milk formula. On the first occasion she con-
sumed 70 ml of formula. She developed urticaria and a
hoarse voice. She then vomited. A similar reaction
occurred after a second formula feed before the diagno-
sis of cow’s milk allergy was made.
Subsequent testing for milk allergy showed a positive
ImmunoCAP 7 kIU/ml (normal <0.35). She was pre-
scribed an EpiPen® Jr auto-injector (Dey Laboratories)
and an anaphylaxis action plan. She was reviewed by a
paediatric allergy dietician. She was placed on Neocate®
elemental formula. The family was very vigilant about
reading food labels to avoid further milk exposure.
In June 2009 she was inadvertently given approxi-
mately 5 ml of Wh2ole®. Within one minute she began
coughing and her voice became hoarse. She started
vomiting. The family successfully deployed her EpiPen® * Correspondence: immunology@xtra.co.nz
LabPlus, Auckland City Hospital, Park Rd, Grafton, Auckland, New Zealand
Ameratunga and Woon Allergy, Asthma & Clinical Immunology 2010, 6:33
http://www.aacijournal.com/content/6/1/33 ALLERGY, ASTHMA & CLINICAL 
IMMUNOLOGY
© 2010 Ameratunga and Woon; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.Jr and her respiratory distress improved with minutes.
She was reviewed in hospital and two hours later had
the outbreak of urticaria. Subsequently she made a full
recovery.
Her mother observed the 5 ml of Wh2ole®p r o v o k e da
more severe reaction than 70 ml of milk formula. This
was in spite of the reduction in the milk-specific IgE
levels from 7 kIU/ml to 1 kIU/ml on ImmunoCAP at
the time of the reaction to Wh2ole®.
Patient 2
Patient 2 is 9 years old. She became distressed at six
months of age when cow’s milk formula was introduced.
She had recurrent vomiting and diarrhoea. Milk allergy
was diagnosed in 2000. She had a 34 kIU/ml IgE to milk
in 2001. She has been carefully avoiding milk products
after the diagnosis.
In May 2009 she visited a café with her parents. She
selected Wh2ole®, which was in the drinks display cabi-
net. It was estimated she had approximately 5 ml of the
drink. She complained of throat discomfort. There were
no breathing difficulties. She then developed abdominal
cramps and vomited. She did not develop urticaria. She
was given antihistamines and placed under observation.
She did not receive epinephrine (adrenaline). She recov-
ered over the next few hours.
Figure 1 Wh2ole® container. The presence of milk protein is indicated in 3 mm letters at the rear of the container.
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Sodium dodecyl sulphate polyacrilamide gel
electrophoresis (SDS-PAGE)
Samples (b-lactoglobulin [Bos d5, Sigma-Aldrich, St
Louis, MO, USA], Wh2ole® and trim milk: containing 1
g/100 ml fat and 3.7 g/100 ml protein) were loaded
onto a 12% polyacrylamide gel and electrophoresis was
performed in a Mini PROTEAN 3 cell (Bio-Rad Labora-
tories, CA, USA) under reducing conditions with
MOPS/SDS buffer for 1 h at 150 V. Decreasing concen-
trations of the purified b-lactoglobulin standard were
used to estimate its concentration in Wh2ole®. After
electrophoresis, the gel was stained with Comassie Bril-
lant Blue G-250.
Western blotting
Western blotting was undertaken as previously
described[5,6]. Following SDS-PAGE, the proteins were
transferred onto a PVDF membrane in a Trans-blot
Electrophoretic Transfer Cell (Bio-Rad). The membrane
was blocked with 1% gelatine in blocking solution (150
mM NaCl, 5 mM EDTA, 50 mM Tris, 0.05% Triton-X)
for 1 h and washed in 0.25% gelatine solution (3 × 5
min). Patient serum was diluted 1 in 10 with 0.25% gela-
tine solution and incubated with the membrane over-
night at room temperature. The membrane was then
incubated in 1:500 biotin-labelled goat anti-human IgE
(Vector, Peterborough, UK) for 1 h, followed by 1:120
000 ALP-linked extravidin (Sigma) for 1 h. Following
each incubation, the membrane was washed (3 × 5 min)
with 0.25% gelatine solution. IgE-binding was visualised
by BCIP/NBT precipitation.
ImmunoCAP inhibition (ICI) studies
Trim milk and Wh2ole® were serially diluted in 1:2 ratio
with 0.9% sodium chloride. Each extract was then added
to patient sera in 1:2 ratio, giving the final dilutions for
the milk ImmunoCAP (1:3 to 1:100 000) and for the b-
lactoglobulin ImmunoCAP (1:300 to 1:100 000). A saline
and patient serum (1:2) sample was included to deter-
mine the baseline. The samples were then incubated for
1 h at room temperature and analysed on the Immuno-
CAP® 250 system (Phadia, Uppsala, Sweden) with Immu-
noCAP discs (Phadia) coated with either bovine milk (f2
CAP) or b-lactoglobulin (f77 CAP).
The response (Fluorescent units-FU) registered on the
ImmunoCAP® 250 system for the two sets of CAPs was
plotted against the dilution factors to generate the
ImmunoCAP inhibition curves.
ImmunoCAP inhibition studies were not undertaken
on the first patient, given the low readings (1 kIU/ml) of
cow’s milk IgE. This would make it difficult to interpret.
ICI studies were undertaken on the second patient and
another patient with high levels of cow’sm i l kI g E .
LabPlus has ethics approval for testing anonymous
serum samples for quality purposes.
The study was approved by the Multi-regional Ethics
Committee of the Ministry of Health in New Zealand
(MEC/09/63/EXP) and the Auckland Hospital Research
Office. Both families gave informed consent.
Results
SDS PAGE electrophoresis
Commassie Blue stained SDS-PAGE of b-lactoglobulin,
Wh2ole® and trim milk is shown in Figure 2. Wh2ole® con-
tains higher proportion of b-lactoglobulin (lane 5 and 6,
MW = 18.5 kDa) than other milk proteins. Wh2ole® has a
lower casein content. Faint bands for caseins can how-
ever be seen in lanes 5 and 6 (figure 2). Densitometry
studies estimated Wh2ole® has approximately 10 g/l of
b-lactoglobulin (Figure 2), which comprises most of its
stated protein content. The b-lactoglobulin concentration
in Wh2ole® is three times that of cow’s milk [7].
Western blotting
Western blotting showed IgE binding in patient sera to
milk proteins including caseins and b-lactoglobulin
(Figure 3). Binding of IgE antibodies to Wh2ole®( l a n e s
2-4) and b-lactoglobulin (lanes 5-7) was also confirmed.
ImmunoCAP inhibition
T h eI C Is t u d i e sw e r eu n d e r t a k e nw i t hb o t hb-lactoglo-
bulin and bovine milk ImmunoCAPs (figure 4). The
cow’s milk inhibition studies have shown pre incubation
of serum with increasing concentrations of trim milk
inhibits the ImmunoCAP reaction to milk Immuno-
CAPs. This homologous inhibition is expected and
serves as an internal control for the assay (figure 5).
Wh2ole® causes partial inhibition at higher
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Figure 2 SDS-PAGE separation of b-lactoglobulin (BLG),
“Wh2ole®” (WW) and milk. MW; Benchmark™ Protein Ladder
(Invitrogen, Carlsbad, CA, USA); lanes 1-4: b-lactoglobulin (5, 2, 1,
and 0.5 μg/μl); lanes 5-7: “Wh2ole®” (1:10, 1:20 and 1:100); lane 8 and
9: milk (neat and 1:2). The band below b-lactoglobulin in lanes 5-9
represents a-lactalbumin.
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Page 3 of 6concentrations (figure 5), confirming there are some
caseins and other allergenic proteins in the preparation
as noted in figure 2.
The ICI with the b-lactoglobulin caps shows inhibition
of binding to the ImmunoCAP by both bovine milk as
well as Wh2ole® (figure 6). The inhibition curves show
that Wh2ole® causes more effective ICI than bovine milk
confirming the higher concentration of b-lactoglobulin.
This supports the results of the SDS-PAGE (figure 2)
indicating that bovine milk has a lower b-lactoglobulin
content than Wh2ole®.
Discussion
Wh2ole® is a product of modern food technology. Pro-
teins from bovine milk have been isolated, concentrated
and added to flavoured water, completely changing its
appearance. This technology has been patented as
“Clearprotein®” (figure 1).
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Figure 3 Western blot showing specific IgE in the serum of patient 2 to milk, Wh2ole® (WW) and b-lactoglobulin (BLG). Lane 1: milk
(1:10); lane 2-4: Wh2ole® (1:10, 1:20, 1:100); b-lactoglobulin (1, 0.5 and 0.1 μg/μl).
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Figure 4 Principle of ImmunoCAP inhibition. As the concentration
of pre incubated trim milk or Wh2ole® (WW) is increased, fewer
specific IgE antibodies are available to bind the RAST discs containing
either b-lactoglobulin (BLG) or bovine milk.
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Figure 5 Bovine milk ICI with trim milk and Wh2ole®.
FU-fluorescent units
Ameratunga and Woon Allergy, Asthma & Clinical Immunology 2010, 6:33
http://www.aacijournal.com/content/6/1/33
Page 4 of 6Wh2ole® is an example of a new class of products
termed “functional foods” [8]. Health Canada (http://
www.hc-sc.gc.ca) defines functional foods as products
that claim health benefits beyond their nutritional value.
These products are sometimes called “nutraceuticals”,
again reflecting their claimed health promoting proper-
ties. Wh2ole® is marketed as an appetite suppressant
between meals (figure 1). High concentrations of whey
proteins have been shown to induce satiety [9]. Manu-
facturers of other functional foods claim better weight
management, improved well being, reduction of diabetes
risk etc [8,10].
The severity of an allergic reaction depends on several
factors including the quantity of allergen consumed, the
level of food-specific IgE antibodies and co-factors such
as exercise. The parents of the first child observed that
a much smaller amount of Wh2ole®p r o v o k e dam o r e
severe clinical reaction than cow’s milk formula. This
was despite the decline in cow’s milk specific IgE in the
intervening period. This observation is consistent with
our in vitro studies showing Wh2ole® has approximately
three times the concentration of b-lactoglobulin com-
pared to bovine milk. b-lactoglobulin is the most abun-
dant protein in bovine whey and is absent from human
breast milk [7].
Wh2ole® should be considered a manufactured “hyper-
allergenic food” as it has a higher concentration of aller-
genic protein compared with its food of origin.
Hyperallergenic foods would also be expected to cause
more severe reactions for a given weight/volume than the
food of origin. Furthermore, allergic patients would be
p r e d i c t e dt or e a c ta tal o w e rt hreshold weight/volume
compared with the food of origin. The ImmunoCAP
inhibition studies shown in figures 5 and 6 also support
our view that Wh2ole® should be considered a hyperaller-
genic food. These foods could be considered the converse
of hypoallergenic formulas where allergens have been
removed or degraded to reduce the risk of allergic
reactions.
We did not undertake food challenges with Wh2ole®a s
anaphylaxis is a contraindication to such procedures.
Our definition of hyperallergenic foods excludes pow-
dered foods which can be artificially concentrated by
adding less water. We have predicted the development
of hyperallergenic foods by the food industry [11].
Consumption of high concentrations of b-lactoglobu-
lin is dangerous for persons with cow’s milk allergy as it
is one of the dominant allergens [7]. Milk allergic
patients with high concentrations of IgE antibodies to b-
lactoglobulin are at particular risk from this product.
Those with IgE antibodies predominantly to caseins may
be at lower risk.
Until now flavoured waters sold in New Zealand have
not contained protein. The original label did state
Wh2ole® contains cow’s milk proteins in 3 mm letters on
the rear of the container (figure 1). It met the food
safety labelling criteria in New Zealand and Australia.
(http://www.foodstandards.gov.au/thecode/). The manu-
facturer has subsequently changed the label of the pro-
duct after becoming aware of these allergic reactions.
We are not aware of any further reactions after this.
Avoidance of allergenic foods is a joint responsibility
between consumers, regulatory authorities and the food
industry. Food allergic patients/parents are advised to
read every food label carefully, as unexpected products
may contain food proteins as illustrated here. Milk is
not usually associated with clear liquid. We are publish-
ing our observations to alert consumers and physicians
worldwide, that these novel products are entering the
market. Allergic consumers need to be particularly vigi-
lant as these products have the potential to cause severe
reactions.
Other sources of unexpected exposure to cow’sm i l k
proteins have been described [12]. Some probiotics con-
tain milk proteins and have triggered anaphylaxis in
cow’s milk allergic patients [13]. Similarly, some asthma
metered dose inhalers use lactose derived from bovine
milk as a stabiliser. Allergic reactions to inhalers have
been described in cow’s milk allergic asthmatic patients
[14].
These examples illustrate the increasing difficulties
food allergic consumers, regulatory authorities and the
food industry will face in the coming years with
advances in food technology. Food proteins are likely to
be encountered in a much broader range of consumer
products.
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Figure 6 b-lactoglobulin ICI with bovine trim milk and Wh2ole®.
FU-fluorescent units.
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A prepublication copy of this paper has been supplied to
Fonterra.
“Fonterra acknowledges and welcomes this research.
We know that families struggle with managing food
allergies and any research that heightens awareness and
prevents incidence of allergic reactions is a positive out-
come. In the case of Wh2ole®, the product met all
New Zealand Food Safety Authority labeling require-
ments. Once we were alerted that people had suffered
allergic reactions from it, we changed the product’s
packaging and worked closely with Allergy New Zealand
to further alert potential allergy sufferers and the wider
community about the milk protein content in the drink.
Wh2ole® was discontinued in early 2010 due to sales not
meeting expectations. We have learnt from this experi-
ence and have taken steps internally to ensure we apply
rigorous standards when communicating detail about
functional ingredients. We remain confident in the enor-
mous international potential of functional ingredients,
such as those used in Wh2ole®, and we will continue to
create innovative new products to meet consumer dietary
and health requirements.”
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